PremiumRatingsInventiva’s Strategic Advancements and Financial Strength Bolster Buy Rating Inventiva’s Strategic Advancements and Financial Positioning Drive Buy Rating Inventiva’s Promising Future: Buy Rating Backed by Phase III Milestone and Financial Stability PremiumThe FlyInventiva initiated with a Buy at TD Cowen Optimistic Buy Rating for Inventiva Driven by Lanifibranor’s Promising Phase 3 Prospects and Safety Profile Inventiva & Japan’s Hepalys start lanifibranor clinical development program PremiumThe FlyInventiva initiated with a Neutral at UBS Inventiva announces DMC recommendation to continue NATiV3 trial as is Inventiva price target lowered to $13 from $14 at H.C. Wainwright